ABSTRACT : Osteoprotegerin (OPG) is a secreted glycoprotein that regulates bone resorption by inhibiting differentiation and activation of osteoclast, thereby potentially useful for the treatment of many bone diseases associated with increased bone loss. In this study, we designed a novel cDNA expression cassette by modifying the potent and mammary glandspecific goat β-casein/hGH hybrid gene construct and examined human OPG (hOPG) cDNA expression in transgenic mice. Six transgenic mice all successfully expressed hOPG in their milk at the level of 0.06-2,000 µg/ml. An estimated molecular weight of the milk hOPG was 55 kDa in SDS-PAGE, which is the same as a naturally glycosylated monomer. This hOPG expression was highly specific to the mammary glands of transgenic mice. hOPG mRNA was not detected in any organs analyzed except mammary gland. Functional integrity of milk hOPG was evaluated by TRAP (tartrate-resistant acid phosphatase) activity assay in bone marrow cell cultures. OPG ligand (OPG-L) treatment increased TRAP activity by two fold but it was completely abolished by co-treatment with transgenic milk containing hOPG. Taken together, our novel cDNA expression cassette could direct an efficient expression of biologically active hOPG, a potential candidate pharmaceutical for bone diseases, only in the mammary gland of transgenic mice.
INTRODUCTION
Bone remodeling is a very dynamic process involving the coordinated phases of bone formation and resorption, which is based on a molecular crosstalk between osteoblasts involved in bone apposition and osteoclasts specialized in bone resorption (Ross, 2006; Filgueira, 2010) . Receptor activator of nuclear factor kB ligand (RANKL) is expressed by osteoblasts and binds to its receptor RANK on the surface of osteoclasts and osteoclast precursors (Udagawa et al., 2000) . These results lead to osteoclast formation, differentiation, activation and consequently bone resorption.
To regulate the balance between bone formation and bone resorption, the RANKL-RANK interaction is inhibited by OPG. OPG produced by osteoblasts acts as a decoy receptor, binding to the RANKL, thus preventing its binding to RANK and subsequent osteoclast activation. As a result, bone resorption is inhibited (Reid & Holen, 2009 ). This triad of proteins, OPG/RANKL/RANK, has been shown in genetic and pharmacology studies to have a critical role in the regulation of osteoclasts and bone resorption (Kostenuik, 2005; Heymann, 2012) .
Osteoprotegerin (OPG) is a secreted glycoprotein and a novel member of the tumor necrosis factor receptor (TNF-R)
superfamily. The critical function of OPG in osteoclastogenesis has been initially revealed by the osteopetrotic phenotype of mice overexpressing it (Lacey et al., 1998; Yasuda et al., 1998) . In contrast, OPG deficient mice exhibit osteoporotic phenotype which is totally reversed by administration of recombinant OPG (Min et al., 2000) .
These results point toward the potential utility of OPG in the treatment of many bone diseases associated with increased Y-Y Sung, C-S Lee Dev. Reprod. Vol. 17, No. 1 (2013) 2 bone loss including post-menopausal osteoporosis, inflammatory arthritides, and metastatic bone tumors (Kostenuik, 2005; Anandarajah, 2009 ).
Transgenic animals are common and useful tools because they give an in vivo look at the ability and impact of foreign gene expression in a biological system (Maga & Murry, 1995) . Production of pharmaceutically active human proteins in the mammary gland of transgenic animals has advanced to the stage of commercial application (Dyck et al., 2003) . The mammary gland is the preferred production site mainly because of the quantities of protein that can be produced in this organ and established methods for extraction and purification of the respective protein (Rudolph, 1999) . Several products derived from the mammary glands of transgenic goats and sheep have progressed to advanced clinical trials (Echelard et al., 2006; Kues & Niemann, 2011 In this study, we designed a novel mammary glandspecific hOPG cDNA expression cassette by modifying the goat β-casein/hGH hybrid gene construct, which previously showed a potent and mammary gland-specific expression of hGH in transgenic mice (Lee, 2006) . Then we examined expression profiles and biological activity of recombinant hOPG protein expressed in transgenic mice harboring the hOPG cDNA expression cassette.
MATERIALS AND METHODS

Construction of hOPG cDNA expression cassette
For an efficient and mammary gland-specific expression of hOPG from its cDNA sequences, a cDNA expression cassette was designed by modifying the goat β-casein/ hGH hybrid gene construct, which previously directed a strong and mammary gland-specific expression of hGH in transgenic mice (Lee, 2006) . The goat β-casein/hGH hybrid gene construct consists of 5' promoter sequence (5.5 kb) of goat β-casein gene and entire structural sequence (2.1 kb) of hGH gene (Fig. 1A) . In order to modify this hybrid gene for hOPG cDNA expression, internal pvuII fragment (984 bp) between exon II and exon V of hGH gene was excised out and ATG codons at exon I and II were replaced with SalI and HpaI cloning sites by PCR using a primer set (5'-AGCTGTCGACGCTACAGGTAAG-3' and 5'-GGCCAGCTGGTGTTAACGATGGGCGCGGAGGAT AGCG-3'). This modification generated a novel cDNA expression cassette ( Goat β-casein/hGH hybrid gene, which was originally described by Lee (2006 of the cassette by blunt ligation (Fig. 1C) . Correct nucleotide sequence of this hOPG expression cassette was confirmed by sequencing before use for DNA microinjection.
Generation of hOPG transgenic mice
Transgenic mice were generated by a standard microinjection method with a NotI/XhoI insert DNA fragment ( 
Enzyme linked immunosorbent assay (ELISA)
Milk samples were collected from founder transgenic females at 10 days of lactation as described previously (Oh & Lee, 2010) 
Northern blot analysis
To determine tissue specificity of hOPG transgene expression, total RNA samples were isolated from various organs of 10 days-lactating mice using Trizol reagent (InVtrogen, USA). Total RNA (20 µg) was separated on 1.0% agarose-formaldehyde gels and then transferred to nylon membranes (Boehringer-Mannheim, Germany). Northern blot hybridizations were performed with 32 P-labeled probes specific to hOPG cDNA sequences.
In vitro osteoclast forming assay
A cell-culture system allowing osteoclast development from hematopoietic precursor cells was used to analyze the biological activity of the milk hOPG (Lacey et al. 1998 . (Table 1 ). In particular, #5 and #6 transgenic mice highly expressed hOPG at the level of 1.6 mg/ml and 2.0 mg/ml, respectively. SDS-PAGE and western blot analysis revealed that the molecular weight of milk hOPG protein is approximately 55 kDa (Fig. 2) , which is the same size as a naturally glycosylated hOPG monomer in cell cultures (Simonet et al., 1997) , and relative signal intensity of samples #5 and #6 was comparable to their concentrations determined by ELISA (Table 1 ). These results demonstrate that the hOPG cDNA expression cassette efficiently produces recombinant hOPG with normal molecular weight in the milk of transgenic mice under the control of a modified goat β-casein/hGH hybrid gene.
Tissue specificity of hOPG expression in transgenic mice
Tissue specificity of hOPG transgene expression was examined using total RNA samples isolated from various organs of highly expressing transgenic mice (#5 and #6) Total RNA samples (20 µg each) isolated from various organs (Mg, mammary gland; Lv, liver; Sp, spleen; Pn, pancreas; Kd, kidney; Lu, lung; Ht, heart; Ty, thyroid gland; Sg, salivary gland; Br, brain) of lactating transgenic (#5 and #6) and non-transgenic control mouse were subjected to northern blot hybridization. Total RNA samples from control mouse were stained with methylene blue to check their integrity and amount (lower panel).
at 10 days of lactation (Fig. 3) . Northern blot analysis revealed that hOPG transgene expression is highly specific to the mammary glands and its transcript is approximately 1.7 kb long. There were no signals in other organs of transgenic mice and all organs examined in control mouse.
The signal intensity of sample #6 was stronger than that of #5. These results demonstrate that hOPG transgene expression directed by goat β-casein/hGH hybrid gene is highly specific to the mammary glands of transgenic mice.
Biological activity of milk hOPG
To examine the biological activity of hOPG in milk, a series of diluted milk together with M-CSF and OPG-L was added into bone marrow cell cultures for 6 days and then TRAP activity of the cell extract was measured.
M-CSF/OPG-L treatment increased TRAP activity by two fold (Fig. 4A) . However, co-treatment with transgenic milk samples (#5 and #6), not with control milk, inhibited this increase in a dose-dependent manner and 2 ng/ml hOPG in milk was sufficient for the complete inhibition (Fig. 4B ).
These results demonstrate that recombinant hOPG in the milk of transgenic mice has a normal biological activity which prevent OPG-L binding to RANK and subsequent osteoclast activation.
DISCUSSION
In this study, we designed a novel mammary glandspecific cDNA expression cassette and examined its expression in transgenic mice. hOPG cDNA was successfully full genomic sequences are generally better than intronless cDNA sequences for an efficient expression in transgenic animals (Rudolph, 1999) , we used cDNA sequences for hOPG expression because its genomic sequence is too long (>29 kb) to manipulate easily. In fact, we modified the goat β-casein/hGH hybrid gene construct for cDNA expression because this hybrid gene previously directed highlevel and mammary gland-specific expression of hGH in most transgenic mice examined (Lee, 2006; Oh & Lee, 2009 , 2010 . A part of hGH gene between exon II and exon V was excised out and two start codons in exon I were replaced with cloning site for cDNA insertion, resulting in hybrid minigene construct containing the first intron, poly(A) signal, and 3' flanking sequences of hGH. Many minigene constructs have successfully expressed in transgenic mice (Persuy et al., 1995; Yan et al., 2006) . The role of intron sequences for transgene expression was well studied in transgenic mice using GH gene and revealed that its first intron is essential for an efficient transgene expression (Palmiter et al., 1991) . Introns could improve transgene expression by a number of different mechanisms (Palmiter et al., 1991) . Some introns contain enhancers or cis-acting elements that influence transcriptional initiation or elongation and some contain sequences that facilitate opening of chromosomal domains, which could affect nucleosome composition and higher-order packing. Alternatively, mRNA splicing process may enhance mRNA stability in the nucleus.
As we had expected, two transgenic mice strongly expressed hOPG from its cDNA sequences only in mammary glands of transgenic mice ( Fig. 2 and 3) . However, the level of hOPG expression in the other four mice was relatively very low when compared to that of highly expressing mice (Table 1) forms. This is particularly the case as far as glycosylation is concerned. Natural hOPG is a glycoprotein secreted as a monomer with 55 -60 kDa or as a disulfide-linked homodimer and its deglycosylated hOPG monomer is about 40 kDa under reducing condition, which is predictable size from its cDNA sequences (Simonet et al., 1997; Tsuda et al., 1997) . We also found 110-kDa dimmers as well as 55-kDa monomer in transgenic milk samples under non-reducing condition (data not shown) and they Dev. Reprod. Vol. 17, No. 1 (2013) hOPG in the Milk of Transgenic Mice 7 inhibited TRAP activity induced by OPG-L in a similar dose range with purified recombinant hOPG from cell cultures (Tsuda et al., 1997) . Therefore it could be demonstrated that hOPG in our transgenic milk is properly glycosylated and its normal biological activity revealed by TRAP activity assay might be attributed to its normal glycosylation pattern (Liu et al., 2003) .
The balance between bone resorption and bone apposition depends on the ratio OPG/RANKL. From the strong evidences for anti-resorptive activity of OPG, many preclinical trials have long been done to evaluate the potential utility of OPG in the treatment for many bone diseases associated with increased bone loss (Anandarajah, 2009) . However, recently the role of OPG in bone cancer remains controversial, as this protein also binds to TRAIL (TNF related apoptosis inducing ligand), another member of the TNF superfamily, resulting in the inhibition of tumor cells apoptosis (Lamoureux et al., 2010) . In these circumstances, OPG could become a survival factor for tumor cells.
Therefore the application of OPG for the treatment of osteolysis should be carefully considered depending on the pathophysiological conditions especially oncological diseases and further understanding of OPG biology will be necessary for its successful clinical applications.
